[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654920":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":16,"armGroups":17,"interventions":28,"overallOfficials":11,"centralContacts":11,"locations":39,"responsibleParty":75,"collaborators":11,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":11,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":11,"enrollmentInfo":86,"targetDuration":11,"studyType":89,"phases":11,"briefSummary":90,"conditions":91,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Betta Pharmaceuticals Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Overall survival period（OS）",null,"Data collection deadline (This study is a retrospective study and there is no predetermined evaluation time).The index date for this study is defined as 4 weeks following complete surgical resection (R0).",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","RETROSPECTIVE","Patients with completely resected (R0) stage IA2 high-risk to IB non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations",[18,23],{"label":19,"type":11,"description":20,"interventionNames":21},"Icotinib Group","Patients with completely resected (R0) stage IA2 high-risk to IB non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations who received adjuvant icotinib therapy after radical resection.",[22],"Drug: Icotinib",{"label":24,"type":11,"description":25,"interventionNames":26},"Routine Observational Group","Patients with completely resected (R0) stage IA2 high-risk to IB NSCLC with positive EGFR-sensitizing mutations who received routine observational follow-up after surgery.",[27],"Other: Routine Observational",[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"DRUG","Icotinib","Icotinib，tablets, usually 125mg per dose (1 tablet), TID, orally",[19],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":11},"OTHER","Routine Observational","Routine Observational Follow-up",[24],[40,60],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55],{"name":56,"role":57,"phone":58,"phoneExt":11,"email":59},"Nan Wu","CONTACT","86-010-88121122","nanwu@bjmu.edu.cn",{"facility":61,"status":42,"city":62,"state":63,"zip":64,"country":46,"countryCode":47,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Shanghai Pulmonary Hospital","Shanghai","Shanghai Municipality","200433",{"type":49,"coordinates":66},[67,68],121.45806,31.22222,{"lat":68,"lon":67},[71],{"name":72,"role":57,"phone":73,"phoneExt":11,"email":74},"Chang Chen","86-021-65115006","chenthoracic@163.com",{"type":76,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100654920","real-world-study-of-icotinib-in-adjuvant-post-surgical-treatment-for-stage-ia2-high-risk-to-ib-egfr-mutant-non-small-cell-lung-cancer-100654920",false,"NCT07806604","Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer","Multicenter, Retrospective, Observational Study of Icotinib for Post-Surgical Adjuvant Therapy in Stage IA2 High-Risk to IB Non-Small-Cell Lung Cancer With Positive EGFR-Sensitive Mutations","Inclusion Criteria:\n\n* 1\\. Histologically confirmed primary non small cell lung cancer (NSCLC), predominantly non squamous histology (including adenocarcinoma or mixed carcinoma with a major adenocarcinoma component)\n* 2\\. Pathologically confirmed stage IA2 high risk to IB NSCLC following complete surgical resection (R0) of primary lung cancer. Disease staging follows the 8th edition of the AJCC\u002FUICC lung cancer staging system.\n* 3\\. Post surgical tumour tissue specimens test positive for EGFR sensitizing mutations using an approved assay\n* 4\\. Patients in the control group received postoperative observation without any anti tumour therapy prior to disease recurrence or metastasis.\n\nExclusion Criteria:\n\n* 1\\. A history of other malignancies within 5 years prior to lung cancer surgery, with the exception of curatively treated malignancies.\n* 2.Prior receipt of systemic anti-tumor therapy for NSCLC within 6 months before lung cancer surgery or before disease recurrence and metastasis.","ALL","18 Years",{"count":87,"type":88},2572,"ESTIMATED","OBSERVATIONAL","This is a multicenter, retrospective, observational real-world study designed based on real-world data. Eligible medical institutions that meet standardized data quality requirements and have an adequate sample size will be enrolled in this study. The treatment group consists of patients with completely resected (R0) stage IA2 high-risk to IB non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations who received adjuvant icotinib therapy after radical resection. The control group includes patients with completely resected (R0) stage IA2 high-risk to IB NSCLC with positive EGFR-sensitizing mutations who received routine observational follow-up after surgery. Propensity score-matched analyses will be conducted between the treatment and control groups to evaluate the efficacy and safety of adjuvant icotinib therapy in this patient population.",[92],"NSCLC (Non-small Cell Lung Cancer)","2026-09-02",{"date":95,"type":96},"2026-09-08","ACTUAL",{"date":98,"type":88},"2026-09",{"date":100,"type":88},"2027-06",{"name":5,"class":6},2]